Strahlentherapie beim nicht metastasierten Lungenkarzinom

Die Entscheidung über die für den individuellen Patienten optimale Therapie sollte in einem multidisziplinären Tumorboard gefällt werden. In diesem Beitrag wird die Rolle der Strahlentherapie bei der Behandlung des nicht metastasierten nichtkleinzelligen Bronchialkarzinoms und des nicht metastasierten limited-disease-kleinzelligen Bronchialkarzinoms dargestellt.

• Literatur

• 1 van Baardwijk A, Tome WA, van Elmpt W. et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol 2012; 105: 145-149
• 2 Palma D, Visser O, Lagerwaard FJ. et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010; 28: 5153-5159
• 3 Auperin A, Le Pechoux C, Rolland E. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-2190
• 4 Martinussen HM, Reymen B, Wanders R. et al. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study. Radiother Oncol 2016; 121: 322-327
• 5 Baumann M, Herrmann T, Koch R. et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011; 100: 76-85
• 6 van Baardwijk A, Wanders S, Boersma L. et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 2010; 28: 1380-1386
• 7 Bradley JD, Paulus R, Komaki R. et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16: 187-199
• 8 Liao Z, Lee JJ, Komaki R. et al. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2018; JCO2017740720
• 9 Antonia SJ, Villegas A, Daniel D. et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. New Engl J Med 2017; 377: 1919-1929
• 10 Le Pechoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 2011; 16: 672-681
• 11 De Ruysscher D, Dingemans AC, Praag J. et al. Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. J Clin Oncol 2018; JCO2017775817
• 12 Turrisi 3rd AT, Kim K, Blum R. et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. The New Engl J Med 1999; 340: 265-271
• 13 van Loon J, De Ruysscher D, Wanders R. et al. Selective nodal irradiation on basis of (18) FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010; 77: 329-336
• 14 Faivre-Finn C, Snee M, Ashcroft L. et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017; 18: 1116-1125
• 15 Le Pechoux C, Dunant A, Senan S. et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009; 10: 467-474